No Data
Aftermarket [Stocks that moved and stocks that were traded]
*Nojima <7419> 2870 +335 Operating profit for the fiscal year ending March 2025 increased by 58.3%. The previous Financial Estimates were a 30.9% increase. *Takamatsu Machinery <6155> 482 +272 The operating loss for the fiscal year ending March 2025 is 0.16 billion yen. The loss has decreased from the previous estimate of 0.392 billion yen. It is estimated to have a profit of 0.138 billion yen in the fiscal year ending March 2026. Dividend policy and mid-term management plan were also announced. *Tokyo Steel <5445> 5880 +420 Operating profit for the fiscal year ending March 2025 increased by 38.1%. A Share Buyback of up to 2.87% of the issued Stocks.
JT, Line Yahoo, Yokogawa Electric, Kawasaki Shipbuilding (7th)
※ The above Calendar is merely a schedule and may be subject to change at the company's convenience.--------------------------------------- May 7 (Wednesday) <165A> SBI Reos <1723> Japan Electric Technology <1870> Yahagi Construction <1967> Yamato <2003> Nitto Fuji <2053> Chubu Feeding <2281> Prima Ham <2344> Heian Ray <2902> Taiyo
Koei Tecmo, Komeda ETC (addition) Rating
Upgrade - Bullish Code Stock Name Brokerage Firm Previous After---------------------------------------------------- <8968> Fukuoka REIT Mizuho "Hold" "Buy" Downgrade - Bearish Code Stock Name Brokerage Firm Previous After---------------------------------------------------- <3481> Mitsubishi Logistics Mizuho "Buy" "Hold" <7752> Ricoh Daiwa
Chordia --- significantly dropped, development halted for the inhibitor of the mucosal-associated lymphoid tissue lymphoma translocation protein 1.
Significantly declined. It has been announced that the strategic licensing partner, Ono Pharmaceutical Co., Ltd. <4528>, has decided to cease the development of the Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT1) inhibitor "CTX-177" for strategic reasons and return the rights related to its development, manufacturing, and commercialization to Chordia Therapeutics. Going forward, discussions will be held with Ono Pharmaceutical regarding the termination of the licensing agreement, and options will be considered.
Stocks that moved and those that were traded in the front market.
* Komatsu Wall <7949> 1780 - The significant increase in the dividend plan raises the appeal of the yield. * Sumitomo Pharma <4506> 787 +100 The substantial upward revision beyond expectations has an impact. * Square Enix HD <9684> 8121 +993 3D Investment emerged as a major shareholder. * S.M.S <2175> 1360 +168 The forecast of double-digit profit growth this period and the strengthening of shareholder returns are well received. * Genky Drug Stores <9267> 3630 +42
MAXIS High Dividend Jpn Eq Actv Man ETF: Extraordinary Report (Domestic Specific Securities)
